Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cartesian Therapeutics (RNAC) EBT: 2015-2025

Historic EBT for Cartesian Therapeutics (RNAC) over the last 11 years, with Sep 2025 value amounting to -$19.5 million.

  • Cartesian Therapeutics' EBT fell 30.10% to -$19.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$83.7 million, marking a year-over-year increase of 59.92%. This contributed to the annual value of -$77.1 million for FY2024, which is 67.69% up from last year.
  • As of Q3 2025, Cartesian Therapeutics' EBT stood at -$19.5 million, which was up 2.72% from -$20.1 million recorded in Q2 2025.
  • In the past 5 years, Cartesian Therapeutics' EBT ranged from a high of $15.0 million in Q2 2024 and a low of -$196.7 million during Q4 2023.
  • Moreover, its 3-year median value for EBT was -$18.0 million (2023), whereas its average is -$30.7 million.
  • As far as peak fluctuations go, Cartesian Therapeutics' EBT spiked by 5,505.67% in 2022, and later slumped by 3,608.62% in 2023.
  • Over the past 5 years, Cartesian Therapeutics' EBT (Quarterly) stood at $12.4 million in 2021, then slumped by 54.71% to $5.6 million in 2022, then plummeted by 3,608.62% to -$196.7 million in 2023, then skyrocketed by 87.66% to -$24.3 million in 2024, then crashed by 30.10% to -$19.5 million in 2025.
  • Its EBT was -$19.5 million in Q3 2025, compared to -$20.1 million in Q2 2025 and -$19.9 million in Q1 2025.